Latest VolitionRX Limited Stories
NAMUR, Belgium, Nov.
Corporate social responsibility initiative supports commitment to long-term quality of life for cancer survivors NAMUR, Belgium, Oct.
Study will assess ability of VolitionRx NuQ® to distinguish between aggressive anaplastic prostate cancer and typical castration-resistant prostate cancer (CRPC) NAMUR, Belgium, Oct.
CEO to Present Data Analysis of Colorectal Cancer Pilot Study of Approximately 1,000 Subjects NAMUR, Belgium, Sept.
Automation will accelerate analysis of blood samples for expanded colorectal cancer screening trial NAMUR, Belgium, Aug.
NAMUR, Belgium, July 1, 2014 /PRNewswire/ -- VolitionRx Limited (OTCQB: VNRX), a life sciences company, today announces
First revenues from VolitionRx Nucleosomics technology NAMUR, Belgium, June 23, 2014 /PRNewswire/ -- VolitionRx Limited
- Growing in low tufty patches.